Northern Dynasty Minerals Stock (AMEX: NAK)

Northern Dynasty Minerals Stock (AMEX:NAK), Trade Ideas

Northern Dynasty Minerals

Northern Dynasty Minerals Ltd is a Canadian mineral exploration company. It has a single operating segment of acquisition, exploration, and development of mineral properties. Its core asset is the Pebble Project located in Alaska, USA. The Pebble project is seeking to develop a significant deposit of copper, gold, molybdenum, and silver into a modern mining operation.

Glacier,Bay,Cruise,-,Alaska,Nature,Landscape.,Glacier,Bay,National

News

Commodities

Legal

Alaska Governor Wants Overhaul Of Mine Permitting, Seeks $700B In Economic Losses

TSX:NDM

Supreme Court Shuts Down Alaskan Pebble Mine Ambitions

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AMAM

AMPE

ARBK

ARDX

AREN

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXNX

BCRX

BFLY

BNZI

BSGM

CROX

CYCC

DADA

DVAX

ELEV

FSLY

HARP

LMDX

NEXI

NKTX

PACB

PRAX

PRTA

RGNX

RVNC

RXST

SHPH

SILK

SNMP

SPEC

STSS

STTK

TCJH

TREE

UPWK

VERO

VINC

ZJYL

Shares of  RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates.

Also, Needham maintained a Buy rating on the stock and raised its price target from $35 to $41.

Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Northern Dynasty Minerals, Ltd. Common Stock

Northern Dynasty Minerals Ltd

NAKANISHI INC TOCHIGI by Nakanishi Inc. Tochigi

Nakanishi Inc

Nakano Corp

NAKED WINES PLC UNSP/ADR by Naked Wines PLC

Naked Wines PLC

Reported Earlier, Northern Dynasty: USACE Declines Engagement In Permit Remand, Following EPA Veto

Alaska Governor Mike Dunleavy has issued a public plea to President Joe Biden to streamline the U.S. <a href="https://www.benzinga.com/topic/mining">mine permitting process</a>. 
The goal is to boost the domestic production of critical minerals and reduce reliance on foreign sources. The governor&#8217;s plea comes amid escalating legal battles and economic ramifications, particularly concerning the Alaskan <a href="https://www.benzinga.com/news/24/01/36558028/supreme-court-shuts-down-alaskan-pebble-mine-ambitions">Pebble Mine project</a>.
"Our message to the Biden administration is, ‘Do everything you can to do everything here in America. Get your permitting processes streamlined,&#8217;" Dunleavy <a href="https://www.nasdaq.com/articles/ceraweek-alaskas-governor-calls-on-biden-to-update-mine-permit-process">told</a> Reuters during the CERAWeek energy conference in Huston.
Dunleavy emphasized the imperative of aligning permitting procedures with national strategic interest, reflecting on a "somewhat nonsensical" push for greater adoption of electric vehicles while blocking cornerstone mining projects.
"If we don't get our permitting processes together, if we don't start to use data and science again instead of emotion, this chaos is going to continue," he noted.
Also Read: <a href="https://www.benzinga.com/news/24/03/37623431/lithium-mining-causes-pollution-but-new-methods-could-showcase-more-eco-friendly-approach"> Lithium Mining Causes Pollution, But New Methods Could Showcase More Eco-Friendly Approach</a>
Central to Dunleavy&#8217;s appeal is the contention that President Biden&#8217;s decision to block the Pebble Mine- the project, spearheaded by Northern Dynasty Minerals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NAK#AMEX">NAK</a>), has been met with staunch opposition due to concerns over its potential ecological impact on Bristol Bay&#8217;s salmon fisheries.
The proposed Pebble mine has been contentious, drawing opposition from environmental groups and Alaska&#8217;s Republican Senators Lisa Murkowski and Dan Sullivan. However, Dunleavy remains steadfast in his support, emphasizing the coexistence of responsible mining practices with the preservation of Alaska&#8217;s natural resources.
"The science is there to be able to develop the mine responsibly," he said. "We can put the safeguards in, and that's why I'm a supporter," he said.
In response to the Biden administration&#8217;s actions, Dunleavy has pursued legal recourse, filing a <a href="https://law.alaska.gov/pdf/press/240315-Complaint.pdf">lawsuit</a> seeking over $700 billion in compensation for Alaska&#8217;s purported economic losses from Pebble Mine&#8217;s obstruction.
Northern Dynasty Minerals has mounted its legal challenges, filing lawsuits to <a href="https://alaskabeacon.com/wp-content/uploads/2024/03/NorthernDynastyFederalClaimsCourt.pdf">overturn</a> the EPA&#8217;s decision and seeking <a href="https://alaskabeacon.com/wp-content/uploads/2024/03/PebbleVsEPA.pdf">compensation</a> for incurred expenses related to the Pebble Mine project.
Still, the local community has its viewpoints. Jason Metrokin, president and CEO of Bristol Bay Native Corp., criticized the legal actions, arguing that the Environmental Protection Agency&#8217;s actions have the Alaskan support.
"It is simply a mistake for Northern Dynasty Minerals and the State of Alaska to continue to pursue the development of what could be North America's largest open pit mine near the headwaters of Bristol Bay's incredible salmon fisheries," Metrokin said in a <a href="https://www.bbnc.net/statement-from-bristol-bay-native-corporation-regarding-legal-challenges-to-epas-final-determination/">statement</a>, noting that fishing business provides over 15,000 jobs and generates around $2 billion in annual economic activity.
Benzinga Mining is the bridge between mining companies and retail investors. Reach out to <a href="mailto:licensing@benzinga.com">licensing@benzinga.com</a> to get started!
Now Read: <a href="https://www.benzinga.com/markets/commodities/24/03/37822526/copper-prices-surge-to-11-month-high-amid-supply-concerns-freeport-ceo-to-politicos-stop-givi">Copper Prices Surge To 11-Month High Amid Supply Concerns, Freeport CEO To Politicos: &#8216;Stop Giving Lip Service&#8217;</a>

HC Wainwright &amp; Co. analyst Heiko Ihle maintains Northern Dynasty Minerals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NAK#AMEX">NAK</a>) with a Buy and lowers the price target from $0.9 to $0.8.

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on Northern Dynasty Minerals, Lowers Price Target to $0.8

The U.S. Supreme Court has shut down Alaska&#8217;s ambition for the Pebble mine due to pollution concerns.
What Happened: The largest North American copper, gold, and molybdenum extraction site has faced nearly two decades of opposition.
Northern Dynasty Minerals (TSX:<a class="ticker" href="https://www.benzinga.com/stock/NDM#TSX">NDM</a>, NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NAK#NYSE">NAK</a>) argued that the proposed mine could provide employment opportunities for thousands of Alaskans. The Vancouver, Canada-based company insisted that the mine would yield substantial resources over a 20-year lifespan, including:
<ul>
<li>6.4 billion pounds of copper</li>
<li>7.4 million ounces of gold</li>
<li>300 million pounds of molybdenum</li>
<li>37 million ounces of silver and</li>
<li>200,000 kilograms of rhenium. </li>
</ul>
Northern Dynasty also intended to store mine waste in the Bristol Bay watershed — home to the world&#8217;s largest sockeye salmon fisheries. 
Last January, the Environmental Protection Agency (EPA) rejected the company&#8217;s proposal in solidarity with Alaskan tribes who remain concerned about the project&#8217;s impact on the pristine watershed.
Why It Matters: The decision is seen as a win for environmental groups. 
Alaskan lawmakers supporting the project filed a motion in July urging the Supreme Court to overturn the EPA&#8217;s veto, arguing that it had the authority to hear the case before lower courts.
&#8220;Alaska tried to persuade the court that this is the rare kind of dispute that the justices should hear as a trial court, without having it go through lower courts first,&#8221; CNN's Supreme Court analyst and University of Texas professor Stephen Vladeck <a href="https://www.cnn.com/2024/01/08/politics/pebble-mine-alaska-copper-epa-supreme-court/index.html">said</a>.
&#8220;Although there's no explanation accompanying today's denial, it stands to reason that a majority of the justices disagreed and were willing to let the case go through ordinary litigation in the lower courts first,&#8221; he added.
Also Read: <a href="https://www.benzinga.com/markets/commodities/24/01/36452207/4-mining-stocks-to-watch-in-2024-aura-oceanagold-alphamin-b2gold">4 Mining Stocks To Watch In 2024: Aura, OceanaGold, Alphamin, B2Gold</a>
What&#8217;s Next: Northern Dynasty&#8217;s stock plummeted 34% following the news. The company also <a href="https://northerndynastyminerals.com/site/assets/files/5039/2024-01-08-nr-ndm-hg98t15f99s.pdf">expressed disappointment</a> in the Supreme Court&#8217;s decision, and believes that the EPA exceeded its regulatory authority.
It is considering legal options to challenge the decision.
Alaska Governor Mike Dunleavy<a href="https://twitter.com/GovDunleavy/status/1744494136445845966"> pledged</a> to continue fighting for the Pebble project, emphasizing its potential importance for copper and critical minerals in an era of fast-tracking renewable energy development. 
Now Read: <a href="https://www.benzinga.com/news/24/01/36539478/as-oversupply-deflates-lithium-bubble-ipo-market-keeps-in-high-spirits">As Oversupply Deflates Lithium Bubble, IPO Market Keeps In High Spirits</a>
Image: Shutterstock

Shares of RxSight, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rxst#NASDAQ">RXST</a>) rose sharply during Monday&rsquo;s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates.
Also, Needham maintained a Buy rating on the stock and raised its price target from $35 to $41.
RxSight shares jumped 20% to $44.31 on Monday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Harpoon Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/harp#NASDAQ">HARP</a>) shares jumped 111.2% to $22.28 after Merck announced it will acquire the company for $23 per share in cash.</li>
<li>Ambrx Biopharma Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amam#NASDAQ">AMAM</a>) jumped 98.1% to $27.00 after Johnson &amp; Johnson announced it will acquire the company in an all-cash merger for a total equity value of approximately $2 billion.</li>
<li>Spectaire Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spec#NASDAQ">SPEC</a>) jumped 75.2% to $2.96.</li>
<li>Nkarta, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nktx#NASDAQ">NKTX</a>) rose 51% to $9.17 as the company announced updated corporate presentation to reflect business and strategic update.</li>
<li>Universe Pharmaceuticals INC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/upc#NASDAQ">UPC</a>) gained 42% to $2.22.</li>
<li>Elevation Oncology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elev#NASDAQ">ELEV</a>) jumped 39.2% to $1.2193.</li>
<li>NexImmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nexi#NASDAQ">NEXI</a>) rose 34.7% to $8.32.</li>
<li>Praxis Precision Medicines, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prax#NASDAQ">PRAX</a>) rose 34% to $33.76 as the company issued update on advancing clinical stage portfolio.</li>
<li>QuantaSing Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qsg#NASDAQ">QSG</a>) gained 31% to $2.0563.</li>
<li>Butterfly Network, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bfly#NASDAQ">BFLY</a>) rose 29.7% to $1.31 as the company announced FDA clearance of handheld ultrasound system, Butterfly iQ3.</li>
<li>Venus Concept Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vero#NASDAQ">VERO</a>) climbed 28% to $1.51.</li>
<li>Ardelyx, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ardx#NASDAQ">ARDX</a>) gained 25.5% to $7.73 after the company provided an update on its progress in 2023 and initial expectations for 2024.</li>
<li>BioCryst Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcrx#NASDAQ">BCRX</a>) rose 20.8% to $7.36 after the company issued preliminary Q4 revenue guidance above estimates. Also the company said it is approaching positive EPS and cash flow in 2H 2025.</li>
<li>Axonics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axnx#NASDAQ">AXNX</a>) jumped 19.9% to $69.03 after the company announced a deal to be acquired by Boston Scientific.</li>
<li>Crocs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crox#NASDAQ">CROX</a>) jumped 18.8% to $102.69 after the company issued strong Q4 and full year 2023 guidance.</li>
<li>LendingTree, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tree#NASDAQ">TREE</a>) rose 17.3% to $33.50.</li>
<li>Wolverine World Wide, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/www#NYSE">WWW</a>) jumped 16.7% to $9.02. Wolverine Worldwide affirmed preliminary 2023 financial results in line with guidance.</li>
<li>Ampio Pharmaceuticals, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ampe#NYSE">AMPE</a>) gained 16.4% to $2.0799 after falling around 8% on Friday.</li>
<li>Shattuck Labs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sttk#NASDAQ">STTK</a>) gained 15.2% to $9.52.</li>
<li>Vincerx Pharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vinc#NASDAQ">VINC</a>) shares rose 14.3% to $1.36 after the company announced compelling clinical efficacy of enitociclib in combination with venetoclax and prednisone in lymphoma.</li>
<li>Cyclacel Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cycc#NASDAQ">CYCC</a>) shares gained 14.1% to $2.84 after jumping over 10% on Friday.</li>
<li>Silk Road Medical, Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/silk#NASDAQ">SILK</a>) rose 13.4% to $12.91.</li>
<li>OPKO Health, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/opk#NASDAQ">OPK</a>) jumped 12.5% to $1.00.</li>
<li>Avadel Pharmaceuticals plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avdl#NASDAQ">AVDL</a>) gained 12% to $16.68 after the company issued a business update.</li>
<li>Fastly, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsly#NYSE">FSLY</a>) jumped 10.5% to $17.88 after RBC Capital upgraded the stock from Underperform to Sector Perform and raised its price target from $12 to $18.</li>
<li>Upwork Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/upwk#NASDAQ">UPWK</a>) gained 10.3% to $15.51 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $13 to $20.</li>
<li>Commercial Metals Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cmc#NYSE">CMC</a>) rose 6.2% to $51.21 following strong quarterly results.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>LumiraDx Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lmdx#NASDAQ">LMDX</a>) shares fell 45.5% to $0.0187. LumiraDx announced its securities will be suspended from trading on Nasdaq at the open of business on Jan. 9th.</li>
<li>Top KingWin Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcjh#NASDAQ">TCJH</a>) dipped 38.8% to $1.18.</li>
<li>Solo Brands, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dtc#NYSE">DTC</a>) dipped 38.7% to $3.6150 after the company lowered full year 2023 revenue guidance below estimates.</li>
<li>Dada Nexus Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dada#NASDAQ">DADA</a>) shares dipped 38.1% to $1.95. Dada Nexus said in the course of its routine internal audit, certain suspicious practices were identified that may cast doubt on certain revenues from the company&#39;s online advertising and marketing services in 2023.</li>
<li>Prothena Corporation plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prta#NASDAQ">PRTA</a>) fell 25.1% to $30.45 after the company issued updates on PRX012, PRX123, Birtamimab and Portfolio programs.</li>
<li>Jin Medical International Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zjyl#NASDAQ">ZJYL</a>) fell 23.4% to $95.00.</li>
<li>MMTec, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mtc#NASDAQ">MTC</a>) fell 22.4% to $1.82.</li>
<li>Evolve Transition Infrastructure LP (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snmp#NASDAQ">SNMP</a>) tumbled 20.8% to $1.33.</li>
<li>Revance Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvnc#NASDAQ">RVNC</a>) fell 20.1% to $6.68 after the company issued preliminary Q4 and FY23 financial results and guidance.</li>
<li>Banzai International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bnzi#NASDAQ">BNZI</a>) shares fell 19.3% to $2.07. Banzai shares jumped around 55% on Friday after the company signed an LOI to acquire IGLeads.</li>
<li>Northern Dynasty Minerals Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nak#NYSE">NAK</a>) dipped 18.8% to $0.3107.</li>
<li>The Arena Group Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aren#NYSE">AREN</a>) shares fell 18.2% to $1.7603 after dipping 17% on Friday.</li>
<li>The Arena Group Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aren#NASDAQ">AREN</a>) dipped 18% to $ 1.7650.</li>
<li>Inspire Veterinary Partners, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ivp#NASDAQ">IVP</a>) declined 16.8% to $0.1881. Inspire Veterinary Partners recently filed a prospectus related to up to a $5 million public offering</li>
<li>Pacific Biosciences of California, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pacb#NASDAQ">PACB</a>) fell 15.1% to $7.99. Pacific Biosciences of California said it sees preliminary FY23 revenue of $200.5 million.</li>
<li>REGENXBIO Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rgnx#NASDAQ">RGNX</a>) fell 14.8% to $14.01. US District Court issued decision on REGENXBIO and University of Pennsylvania NAV technology patent infringement lawsuit.</li>
<li>Revance Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvnc#NASDAQ">RVNC</a>) fell 13.6% to $7.21. Revance issued corporate update, preliminary Q4 and FY23 financial results, and financial outlook.</li>
<li>BioSig Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bsgm#NASDAQ">BSGM</a>) fell 13.6% to $0.35. On Jan. 5, BioSig Technologies received a letter from Nasdaq notifying company has regained compliance with Nasdaq Listing Rule 5550(b)(2).</li>
<li>Bright Health Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bhg#NYSE">BHG</a>) dipped 12.8% to $10.00.</li>
<li>Safe and Green Development Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgd#NASDAQ">SGD</a>) shares fell 11.3% to $1.80 after jumping 49% on Friday.</li>
<li>Argo Blockchain plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arbk#NASDAQ">ARBK</a>) fell 11.1% to $3.11 after announcing &pound;7.8 million ($9.9 million) placing.</li>
<li>Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/shph#NASDAQ">SHPH</a>) dipped 10.7% to $0.5146. Shuttle Pharmaceuticals received FDA approval to proceed with Phase II clinical trial of ropidoxuridine for the treatment of patients with glioblastoma.</li>
<li>Paragon 28, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fna#NYSE">FNA</a>) fell 9.6% to $11.83. Paragon 28 said it sees preliminary fourth-quarter revenue of $60.3 million to $60.6 million.</li>
<li>Sharps Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stss#NASDAQ">STSS</a>) fell 8.3% to $0.4032 after jumping 12% on Friday.</li>
<li>Dynavax Technologies Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dvax#NASDAQ">DVAX</a>) dipped 7.5% to $13.63. Dynavax sees preliminary 2023 HEPLISAV-B vaccine net product revenue of $213 million.</li>
<li>The Boeing Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ba#NYSE">BA</a>) fell 7% to $231.69 after an exit door blew out of a 737 aircraft during a commercial flight.</li>
<li>Spirit AeroSystems Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/spr#NYSE">SPR</a>) fell 6.5% to $29.67 after an exit door blew out of a 737 aircraft during a commercial flight. Spirit Aerosystems was a vendor involved with the faulty door.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/01/36528274/cramer-says-this-major-healthcare-stock-is-ridiculously-cheap-and-doing-so-many-great-th"> Cramer Says This Major Healthcare Stock Is &#39;Ridiculously Cheap And Doing So Many Great Things&#39; </a>

Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Northern Dynasty Minerals Ltd. (TSX:<a class="ticker" href="https://www.benzinga.com/stock/NDM#TSX">NDM</a>)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NAK#NYSE">NAK</a>) ("Northern Dynasty" or the "Company") reports that the US Supreme Court has denied Alaska's petition to review its claims that the EPA veto of the Pebble Project was illegal. John Shively, CEO of its 100%-owned U.S.-based subsidiary Pebble Limited Partnership ("Pebble Partnership" or "PLP") made the following statement regarding the decision:
"While it is a disappointing decision, it is important to note that this is not a comment on the arguments put forward by the state. We have long stated our belief that the EPA has acted outside of its regulatory authority and that remains our position today. The legal issues raised by the state will now work their way through the federal courts. We will also evaluate our legal options in contesting the extraordinary steps the EPA has taken to preemptively stop the Pebble Project. Pebble is an important project for Alaska and the nation. It could create jobs for Alaskans, provide an economic catalyst for the state and provide a much-needed source of critical minerals for the long-term safety and security of the United States."

Pebble Responds To U.S. Supreme Court Decision To Deny Alaska's Petition; Says "While It Is A Disappointing Decision, It Is Important To Note That This Is Not A Comment On The Arguments Put Forward By The State."

Northern Dynasty's Faces Further Delay As Alaska District Of The US Army Corps Of Engineers Gets Sixth Extension

Northern Dynasty Minerals Ltd. (TSX:<a class="ticker" href="https://www.benzinga.com/stock/NDM#TSX">NDM</a>);(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NAK#NYSE">NAK</a>) ("Northern Dynasty" or the "Company") reports it has received an initial $2 million royalty investment under the second tranche investment of the Company's royalty agreement dated July 26, 2022 (the "Royalty Agreement'). The Company and the royalty investor ("the Royalty Holder") have also agreed to amend the terms of the Royalty Agreement ("the Amendment") in order to increase flexibility of payment installments and to extend the original July 25, 2024 expiration date. All currency figures are U.S. dollars.
Under the Revised Agreement, the Royalty Holder receives the right to fund the second $12 million tranche in six equal installments of $2 million each ("Additional Payment Installment"), with the right to receive approximately 0.33% of the payable gold production and 1% of the payable silver production from the Pebble Project per Additional Payment Installment made (representing 1/6 of the aggregate royalty under the second tranche). The Company received the first $2 million upon execution of the Amendment.
In the event the Royalty Holder completes all six installments (for a total of $12 million) on or before July 26, 2024, the expiration date of the Royalty Agreement will be extended until July 26, 2025. The remaining three tranches of $12 million each, as described in the Company's July 27, 2022 news release, have not been similarly subdivided, and the aggregate total purchase price of $60 million and maximum royalty rates (10% of payable gold production and 30% of payable silver production) remain unchanged from the original Royalty Agreement.
"We are working with the Royalty Holder to ensure this funding vehicle is structured in the most effective way for both parties," said Ron Thiessen, President and CEO of Northern Dynasty Minerals. "We have agreed with the Royalty Holder to provide flexibility by dividing the $12 million second tranche into six, $2 million payments. The first of these $2 million payments has been made. In addition, we have agreed that if the Royalty Holder completes the full $12 million second tranche by July 26, 2024, we will extend the expiration date for one year."
"Our objective remains to receive the full $60 million which, when completed, increases our financial liquidity. It also allows us to continue the pursuit of the responsible development of the Pebble Project, one of if not the most important critical minerals and metals deposits for the United States of America and the State of Alaska. This project will only be developed with standards that assure the participation of people in the region, Alaska as a whole, and with assurances the environment and subsistence and commercial fisheries are safeguarded at all times," Mr. Thiessen continued.
As reported on July 27, 2022, the first tranche of $12 million was received by the Company in return for the right of the Royalty Holder to receive 2% of the payable gold production and 6% of the payable silver production from the Pebble Project, in each case after accounting for a notional payment by the Royalty Holder of $1,500 per ounce of gold and $10 per ounce of silver, respectively, for the life of the mine. If, in the future, spot prices exceed $4,000 per ounce of gold or $50 per ounce of silver, then the Company will share in 20% of the excess price for either metal. Additionally, the Company will retain a portion of the metal produced for recovery rates in excess of 60% for gold and 65% for silver, and so is incentivized to continually improve operations over the life of the mine.

Contracts

Northern Dynasty Receives Initial $2M Advance Under Second Tranche Of Amended Royalty Agreement

Northern Dynasty's Faces Another Delay As Alaska District Of The US Army Corps Of Engineers Gets Fifth Extension

<h3>Gainers</h3>
<ul>
<li>Palisade Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pali#NASDAQ">PALI</a>) shares jumped 114% to $1.47. Palisade Bio transformed GI-focused pipeline through exclusive worldwide licensing agreement with Giiant Pharma, Inc. for multiple oral drug candidates targeting inflammatory bowel disease.</li>
<li>FOXO Technologies Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/foxo#NYSE">FOXO</a>) gained 51.3% to $0.2164 after the company&#39;s FOXO LIFE subsidiary announced an agreement with Atrio, expanding its distribution through Atrio/Singular&#39;s sales network.</li>
<li>iCoreConnect Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icct#NASDAQ">ICCT</a>) shares climbed 46% to $9.83. iCoreConnect announced new version of its iCoreExchange encrypted HIPAA email and referral network.</li>
<li>Marin Software Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrin#NASDAQ">MRIN</a>) rose 29% to $0.5535 after the company reported HubSpot integration.</li>
<li>AeroVironment, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avav#NASDAQ">AVAV</a>) jumped 28.7% to $122.65 after the company reported better-than-expected results for its first quarter.</li>
<li>FLJ Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flj#NASDAQ">FLJ</a>) shares jumped 23.1% to $0.2401. FLJ Group is scheduled to hold its 2023 annual general meeting on Sept. 18, 2023.</li>
<li>Power REIT (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pw#NYSE">PW</a>) gained 22.4% to $1.2550.</li>
<li>Theratechnologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/thtx#NASDAQ">THTX</a>) gained 19% to $1.2250.</li>
<li>Cidara Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cdtx#NASDAQ">CDTX</a>) climbed 18.5% to $0.94 after Janssen elected to proceed under its license agreement relating to influenza candidate.</li>
<li>Adamas One Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jewl#NASDAQ">JEWL</a>) gained 18.3% to $0.9105. Adamas One received Nasdaq notification of non-compliance with listing rule 5250(c)(1).</li>
<li>9F Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jfu#NASDAQ">JFU</a>) gained 15.3% to $2.8699.</li>
<li>Mitek Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mitk#NASDAQ">MITK</a>) shares surged 15% to $13.00 after the company posted first-quarter results and raised FY23 guidance.</li>
<li>NextGen Healthcare, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxgn#NASDAQ">NXGN</a>) rose 14.5% to $23.54 after the company agreed to be acquired by Thoma Bravo for $23.95 per share in cash.</li>
<li>Gogo Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gogo#NASDAQ">GOGO</a>) climbed 14.5% to $12.75. Gogo announced a $50 million share repurchase program.</li>
<li>Northern Dynasty Minerals Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nak#NYSE">NAK</a>) gained 14.1% to $0.3125. Northern Dynasty&#39;s pebble project received positive assessment with strong economic prospects and benefits for Alaska.</li>
<li>Anghami Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/angh#NASDAQ">ANGH</a>) climbed 13.1% to $0.95.</li>
<li>Hitek Global Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hkit#NASDAQ">HKIT</a>) gained 11.5% to $30.50.</li>
<li>Bridger Aerospace Group Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/baer#NASDAQ">BAER</a>) jumped 9.6% to $7.68.</li>
<li>System1, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sst#NYSE">SST</a>) rose 8.2% to $1.99. System1 confirmed receipt of non-binding indication of interest for Total Security Limited from Just Develop It.</li>
<li>NeuBase Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nbse#NASDAQ">NBSE</a>) shares gained 8% to $1.2403 after jumping over 22% on Tuesday.</li>
<li>Roku, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roku#NASDAQ">ROKU</a>) gained 7.8% to $90.22 after the company disclosed plans to cut workforce by 10% and raised third-quarter revenue guidance above the consensus.</li>
<li>TradeUP Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/uptd#NASDAQ">UPTD</a>) shares gained 7.5% to $13.75 after falling 42% on Tuesday.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>EZGO Technologies Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ezgo#NASDAQ">EZGO</a>) shares dipped 72.9% to $0.4767 after the company reported pricing of $10 million registered direct offering.</li>
<li>Verb Technology Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/verb#NASDAQ">VERB</a>) fell 29.7% to $2.25. Verb Technology Company shares jumped 347% on Tuesday after the completed and launched a technology integration and strategic relationship with global social media platform TikTok.</li>
<li>The Alkaline Water Company Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wter#NASDAQ">WTER</a>) dipped 26.7% to $0.4505.</li>
<li>Lion Group Holding Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lghl#NASDAQ">LGHL</a>) declined 26.2% to $2.17.</li>
<li>Akoustis Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akts#NASDAQ">AKTS</a>) fell 25% to $1.2388. Akoustis Technologies reported fourth-quarter FY23 revenue growth of 60.2% year-on-year to $8.33 million, missing the consensus of $8.44 million.</li>
<li>AMC Entertainment Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/amc#NYSE">AMC</a>) tumbled 23% to $10.49 after the company entered an equity distribution agreement for up to 40 million shares at an at-the-market program.</li>
<li>Clever Leaves Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clvr#NASDAQ">CLVR</a>) fell 22% to $3.23.</li>
<li>Overstock.com, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ostk#NASDAQ">OSTK</a>) fell 21.2% to $21.62. Bed Bath &amp; Beyond, operated by Overstock.com, issued an update on its third-quarter performance.</li>
<li>Helius Medical Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hsdt#NASDAQ">HSDT</a>) declined 21% to $7.96. Helius Medical Technologies recently gained compliance with all applicable NASDAQ listing criteria.</li>
<li>Blue Star Foods Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bsfc#NASDAQ">BSFC</a>) dipped 18.8% to $0.5349. Blue Star Foods said its soft-shell crab operations in South Carolina received a license renewal from the South Carolina Department of Natural Resources.</li>
<li>CXApp Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cxai#NASDAQ">CXAI</a>) shares fell 18.5% to $3.9188 after jumping over 52% on Tuesday. CXApp announced AI-based augmented reality solution for RTO (Return To Office).</li>
<li>1847 Holdings LLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/efsh#NASDAQ">EFSH</a>) declined 17.2% to $0.0769.</li>
<li>Digital Brands Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dbgi#NASDAQ">DBGI</a>) fell 16.8% to $11.75 after jumping around 32% on Tuesday. The company announced the closure of its offering for the issuance and sale of 513,875 shares of common stock, fetching gross proceeds of approximately $5.0 million.</li>
<li>SIGNA Sports United N.V. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ssu#NYSE">SSU</a>) declined 16.4% to $0.6701.</li>
<li>RVL Pharmaceuticals plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvlp#NASDAQ">RVLP</a>) shares fell 16.3% to $0.1165 after jumping 26% on Tuesday. RVL Pharmaceuticals announced a $5 million registered direct offering of 11,870,846 shares priced at $0.4212 per share.</li>
<li>Applied Molecular Transport Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amti#NASDAQ">AMTI</a>) fell 14.9% to $0.2012 after surging 30% on Tuesday.</li>
<li>Axcella Health Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axla#NASDAQ">AXLA</a>) fell 14.6% to $0.3031.</li>
<li>NWTN Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nwtn#NASDAQ">NWTN</a>) dropped 14.6% to $7.95.</li>
<li>Asana, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/asan#NYSE">ASAN</a>) shares declined 14.5% to $18.50. Asana reported upbeat results for its second quarter. The company said it sees FY24 adjusted loss of 42 cents to 39 cents per share and revenues of $642 million to $648 million.</li>
<li>DocGo Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dcgo#NASDAQ">DCGO</a>) fell 14% to $7.03.</li>
<li>EpicQuest Education Group International Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eeiq#NASDAQ">EEIQ</a>) fell 12.3% to $1.21 after jumping 29% on Tuesday.</li>
<li>First Wave BioPharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fwbi#NASDAQ">FWBI</a>) fell 12.2% to $0.3950 after jumping 55% on Tuesday.</li>
<li>Photronics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plab#NASDAQ">PLAB</a>) fell 11.1% to $20.89 after the company reported worse-than-expected third-quarter results owing to sluggish demand in some end markets.</li>
<li>American Lithium Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amli#NASDAQ">AMLI</a>) declined 9.9% to $1.4050.</li>
<li>Xponential Fitness, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/xpof#NYSE">XPOF</a>) fell 8.3% to $20.63. Xponential Fitness issued three-year operating targets and issued strategic updates ahead of analyst and investor day.</li>
<li>Core &amp; Main, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cnm#NYSE">CNM</a>) fell 7% to $29.40. Core &amp; Main reported second-quarter FY23 sales of $1.861 billion flat year-over-year, missing the consensus of $1.88 billion.</li>
<li>Snap Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/snap#NYSE">SNAP</a>) fell 6% to $9.82.</li>
<li>Enbridge Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/enb#NYSE">ENB</a>) shares fell 5% to $33.53. Enbridge entered into three separate definitive agreements with Dominion Energy, Inc. to acquire EOG, Questar and PSNC for an aggregate purchase price of $14.0 billion.</li>
<li>Telef&oacute;nica, S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tef#NYSE">TEF</a>) shares declined 3.8% to $4.0199. Saudi Telecom Co. bought a stake worth $2.25 billion in Telef&oacute;nica.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/23/09/34279149/bitcoin-ethereum-flat-synthetix-emerges-as-top-gainer"> Bitcoin, Ethereum Flat; Synthetix Emerges As Top Gainer</a>

AKTS

AMLI

AMTI

ANGH

ASAN

AVAV

AXLA

BAER

BSFC

CDTX

CLVR

CXAI

DBGI

DCGO

EEIQ

EFSH

EZGO

FOXO

FWBI

GOGO

HKIT

HSDT

ICCT

JEWL

LGHL

MITK

MRIN

NBSE

NWTN

NXGN

OSTK

PALI

PLAB

ROKU

RVLP

SNAP

THTX

UPTD

VERB

WTER

XPOF

Why Core & Main Are Trading Lower By 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Northern Dynasty's Pebble Project Receives Positive Assessment With Strong Economic Prospects And Benefits For Alaska

Northern Dynasty Minerals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NAK#AMEX">NAK</a>) reported quarterly losses of $(0.01) per share. This is unchanged from the same period last year.

Earnings

Northern Dynasty Minerals Q2 GAAP EPS $(0.01), Same YoY

HC Wainwright &amp; Co. analyst Heiko Ihle maintains Northern Dynasty Minerals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NAK#AMEX">NAK</a>) with a Buy and raises the price target from $0.8 to $0.9.

HC Wainwright & Co. Maintains Buy on Northern Dynasty Minerals, Raises Price Target to $0.9

- Form 6 Filing
&nbsp;
Northern Dynasty prepared its Financial Statements on the basis that Northern Dynasty will continue as a going concern.&nbsp; At March&nbsp;31, 2023, the Company had working capital of&nbsp;$8.1&nbsp;million.&nbsp; Northern Dynasty has prioritized the allocation of its financial resources to meet key corporate and Pebble Project expenditure requirements in the near term, including the funding of the appeal and remand of the ROD and legal challenges to EPA&rsquo;s Final Determination.&nbsp; Additional financing will be required to progress any material expenditures at the Pebble Project and for working capital.&nbsp; Northern Dynasty&rsquo;s continuing operations and the underlying value and recoverability of the amounts shown for mineral property interest are entirely dependent upon the existence of economically recoverable mineral reserves at the Pebble Project, the ability of the Company to finance its operating costs, the completion of the exploration and development of the Pebble Project, the Pebble Partnership obtaining the necessary permits to mine, and on future profitable production at the Pebble Project.&nbsp; Furthermore, failure to continue as a going concern would require that Northern Dynasty&#39;s assets and liabilities be restated on a liquidation basis, which would likely differ significantly from their going concern assumption carrying values.

Management

Northern Dynasty's Ability To Continue As A Going Concern Is Dependent On Its Ability To Finance Its Operating Costs, Complete Exploration And Development, Obtain Necessary Permits To Mine, And Achieve Future Profitable Production At The Pebble Project

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates Northern Dynasty Minerals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NAK#AMEX">NAK</a>) with a Buy and maintains $0.8 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Northern Dynasty Minerals, Maintains $0.8 Price Target

Northern Dynasty Minerals Q4 EPS $(0.01), Same YoY

Offerings

Northern Dynasty Minerals Ltd Files For Mixed Shelf Of Up To $50M

Northern Dynasty Minerals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NAK#AMEX">NAK</a>) reported quarterly losses of $(0.01) per share. This is a 60 percent increase over losses of $(0.02) per share from the same period last year.

Northern Dynasty Minerals Q3 EPS $(0.01) Up From $(0.02) YoY

Northern Dynasty Minerals Ltd. (TSX:<a class="ticker" href="https://www.benzinga.com/stock/NDM#TSX">NDM</a>)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NAK#NYSE">NAK</a>) (&quot;Northern Dynasty&quot; or the &quot;Company&quot; or &quot;NDM&quot;) reports that John Shively, CEO of its 100%-owned U.S.-based subsidiary Pebble Limited Partnership (&quot;Pebble Partnership&quot; or &quot;PLP&quot;) released the following statement about last Friday&#39;s Transportation and Infrastructure (&quot;T&amp;I&quot;) Committee report on the Pebble mine. The statement, reiterated in full below, read:
&quot;To begin, we have not had time to fully review the 163 page report. It was clearly shared with some of the media before it was shared with us. Thus, our comments are initial and we will have more to share with the public.&quot;
&quot;We want to be absolutely clear, however, that to the extent the report contains any suggestion that we tried to mislead regulators in any way, it is categorically wrong and misinformed of the realities of the Pebble permitting process.&quot;
&quot;We have been forthright and clear in all of our public communications and with regulators that Pebble would need to be permitted in phases. We have been equally clear with all stakeholders that: (a) we were planning to construct and operate an initial mine at Pebble for twenty years, (b) that initial plan did not mine the entire resource, and (c) at some future time, we would likely consider an expansion, but had no formal specific plans for additional mining at Pebble (nor could we given the contingencies associated with the initial phase submitted for permitting). This information was also presented in the Environmental Impact Statement (&quot;EIS&quot;) process and related documents for the project. A quick search on the term &quot;expansion scenario&quot; which was what they used for the large mine in the EIS yields more than 300 hits scattered throughout the EIS.&quot;
&quot;We have been up front that the resource and opportunity at Pebble are significant and that any future opportunity would require another comprehensive permitting process.&quot;
&quot;We openly shared all of this with the committee and are extremely disappointed with the politicization of the so-called review of the project that is inconsistent with reality. We look forward to laying out the essential context missing from the report.&quot;
Ron Thiessen, President and CEO of Northern Dynasty Minerals, added the following comment, &quot;Here we go again with politics replacing &quot;reality, science and facts&quot;. We have been consistent in our disclosure for more than a decade that we are permitting a 20 year mine and, although the resource is much, much larger than that, any additional work, extension or expansion would require extensive permitting, planning and approvals before it could be undertaken. For anyone to conclude that anything materially different from what was in our proposed mine plan could be built and operated without an entirely new permit approval process fundamentally fails to understand how the permitting process works in the U.S. The T&amp;I committee is playing a risky, short-sighted political game in D.C., with a misguided goal of inhibiting domestic mining. The current adminstration&#39;s persistent opposition to mining and mine development in the U.S. is bad for local economic development in Alaska, bad for the energy transition and bad for the vast majority of the U.S. population.&quot;

Northern Dynasty Reports John Shively, CEO Of Pebble Partnership, Releases Statement Regarding Last Friday's Transportation And Infrastructure Committee Report On The Pebble Mine

U.S. Army Corps extends deadline to comment on Pebble mining project

Heiko Ihle, an analyst from H.C. Wainwright, reiterated the Buy rating on Northern Dynasty Minerals (NAK – Research Report). The associated price t...

Northern Dynasty Minerals: A Buy Rating Amid EPA Dispute and Potential Site Risks – An Analysis

Northern Dynasty announces $15 million convertible notes offering

H.C. Wainwright analyst Heiko Ihle reiterated a Buy rating on Northern Dynasty Minerals (NAK – Research Report) today and set a price target of $0....

Buy Rating Affirmed for Northern Dynasty Minerals Amid Financial Strengthening and Permitting Advances

Northern Dynasty bounces off Monday's rout as Supreme Court rebuffs Pebble Mine challenge

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
I&rsquo;m about to drop a truth bomb about speculative stocks under $1.



Back when I was a freshman in college, the on-campus security officer had this to say: &ldquo;Tijuana? You don&rsquo;t wanna.&rdquo; Subsequently, the crowd erupted in laughter but the officer got his point across. Yes, Tijuana is an exciting and vibrant city, no doubt about it. However, people &ndash; especially young underage college students &ndash; can get carried away.



That&rsquo;s the reality behind speculative stocks under $1. It&rsquo;s like Tijuana, where the same restrictions you might find in the U.S. (for your own protection) might not be so prevalent south of the border. So, if you&rsquo;re going to speculate, speculate responsibly.



That&rsquo;s all. Here are some speculative stocks under $1 to mull over.



<h2>Akoutsis Technologies (AKTS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/penny-stocks-1600-300x169.jpg" alt="A concept image of a penny sitting on a stock chart"><div>Source: Billion Photos / Shutterstock.com</div></div>Based in North Carolina, Akoustis Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/akts-stock-quote/">AKTS</a>) is a specialist in the radio frequency (<a href="https://investorplace.com/stock-quotes/rf-stock-quote/">RF</a>) industry. Fundamentally, RF technology plays a <a href="https://cellbusters.com/rf-technology/#:~:text=It's%20used%20for%20applications%20like,many%20wireless%20device%20detection%20systems.">critical role in protecting information and assets</a> across wireless device networks. In terms of applications, industry products are used in GPS trackers, weather forecasting, satellite communications, and more. If you think this space is relevant, it is.



Even better, Akoustis has been a revenue monster. For example, the company posts a <a href="https://www.gurufocus.com/stock/AKTS/summary?search=akts">three-year revenue growth rate of 100.3%</a>. Of course, such a top-line performance won&rsquo;t last indefinitely. Nevertheless, analysts project that by the end of this year, Akoustis will generate sales of $32.86 billion. If so, that would translate to growth of 21.2% from last year&rsquo;s tally.



What&rsquo;s more, in 2025, the company may post revenue of $53.62 million. In that case, growth would soar to 63.2% from 2024&rsquo;s projected sales.



Of course, nothing&rsquo;s for free on Wall Street. You want to play? AKTS is highly risky, losing 26% year-to-date. Still, analysts rate shares a <a href="https://www.tipranks.com/stocks/akts/forecast">moderate buy</a> with a $1 price target. That makes it one of the speculative stocks under $1.



<h2>Vertical Aerospace (EVTL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/penny-stocks-300x169.png" alt="Stacks of pennies representing penny stocks. Nano-Cap Penny Stocks"><div>Source: John Brueske / Shutterstock.com</div></div>Electric vertical takeoff and landing (eVTOL) aircraft seem to be all the rage these days and Vertical Aerospace (NYSE:<a href="https://investorplace.com/stock-quotes/evtl-stock-quote/">EVTL</a>) wants a piece of the pie. <a href="https://vertical-aerospace.com">Per its website</a>, Vertical is pioneering electric aviation through its VX4 aircraft. It boasts a cruising speed of 150 miles per hour and a range of 100 miles. For environmentalists, the <a href="https://vertical-aerospace.com/meet-the-vx4/">VX4 carries the advantage of zero emissions</a>.



Although it&rsquo;s an intriguing idea for speculative stocks under $1, that&rsquo;s what it largely is: an idea. Looking at its financials, the company <a href="https://www.gurufocus.com/stock/EVTL/financials">does not generate revenue</a>. Other states don&rsquo;t seem particularly encouraging. For example, it sees a three-year EBITDA growth rate of 88.7% below breakeven. However, on the positive side, Vertical enjoys a <a href="https://www.gurufocus.com/stock/EVTL/summary">cash-to-debt ratio of 26.69X</a>.



Will that be enough to keep EVTL stock a float? That&rsquo;s a major question mark. Over the past 52 weeks, EVTL lost more than 64% of equity value. On the &ldquo;positive&rdquo; side, shares trade hands at 68 cents. That&rsquo;s much closer to the 52-week low of 50.8 cents than it is to the 52-week high of $2.35. It&rsquo;s possible, then, that EVTL could bounce higher.



<h2>Emcore (EMKR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/08/penny-stocks-1600-300x169.jpg" alt="Page of newspaper with words penny stocks. high return penny stocks"><div>Source: Vitalii Vodolazskyi / Shutterstock.com</div></div>An aerospace and defense specialist, Emcore (NASDAQ:<a href="https://investorplace.com/stock-quotes/emkr-stock-quote/">EMKR</a>) represents one of the speculative stocks under $1 that I&rsquo;ve discussed previously. As a market wager, it could be intriguing for its focus on autonomous platforms. Specifically, drone warfare has become one of the most pivotal developments in modern warfare. Moving forward, more conflicts may see the increased deployment of unmanned aerial vehicles.



Of course, control such vehicles effectively will be key. And that cynically could see Emcore rise far higher from its current position. Further, analysts believe the company has the goods to back up its potential. By the end of 2024, they anticipate that revenue will reach $101.6 million. That would be up 4% from last year&rsquo;s tally of $97.72 million.



Looking out to 2025, they anticipate revenue to hit $114.66 million. If so, that&rsquo;s almost a 13% lift from projected 2024 sales.



Is it risky? Absolutely &ndash; we&rsquo;re talking about an enterprise with a market capitalization of only $32.64 million. However, analysts rate shares a <a href="https://www.tipranks.com/stocks/emkr/forecast">unanimous strong buy</a> with a $1.18 price target, up over 179%.



<h2>Northern Dynasty Minerals (NAK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/penny-1600-300x169.jpg" alt="Pennies in a jar on top of a background of blurred pennies. Penny stocks."><div>Source: John Brueske / Shutterstock</div></div>A metals and mining exploration firm, Northern Dynasty Minerals (NYSEAMERICAN:<a href="https://investorplace.com/stock-quotes/nak-stock-quote/">NAK</a>) focuses on what its website calls the world-class <a href="https://northerndynastyminerals.com">Pebble Project in Alaska</a>. Further, the company claims that it&rsquo;s the world&rsquo;s most significant undeveloped copper and gold resource. Therefore, if Northern Dynasty can live up to its potential, NAK could easily be one of the top speculative stocks under $1.



To be sure, as an exploration firm, the company doesn&rsquo;t generate any revenue. Further, in 2022, its free cash flow landed at $18 million below breakeven. On a trailing-12-month (<a href="https://investorplace.com/stock-quotes/ttm-stock-quote/">TTM</a>) basis, the cash burn came out to $17 million. It&rsquo;s something to keep in mind &ndash; we&rsquo;re dealing more with narratives here rather than fiscal substance.



Still, on the plus side, the company features a <a href="https://www.gurufocus.com/stock/NAK/summary?search=nak">decently stable balance sheet</a>. In addition, the pricing profile may be compelling to market gamblers. Presently priced at 26 cents, NAK&rsquo;s 52-week low sits at 21 cents whereas the 52-week high lands at 43 cents. Therefore, it could be a relative bargain.



H.C. Wainwright&rsquo;s Heiko Ihle is the sole analyst covering NAK stock with a &ldquo;buy&rdquo; rating. As well, the expert sees a <a href="https://www.tipranks.com/stocks/nak/forecast">90-cent target</a>, implying nearly 244% upside potential.



<h2>Outlook Therapeutics (OTLK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/penny-stocks-stack-chart-300x169.jpg" alt="a stack of pennies and a calculator lay stop a graph of market movements. Penny Stocks"><div>Source: Shutterstock</div></div>A pre-commercial biotechnology enterprise, Outlook Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/otlk-stock-quote/">OTLK</a>) is dedicated to developing therapies for the preservation of vision. Specifically, the company is working to develop and launch the first ophthalmic formulation approved by the Food and Drug Administration (FDA) of bevacizumab for use in retinal indications. Its main disease focus centers on the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and branch retinal vein occlusion (BRVO).



To be sure, undersized biotech names represent one of the most volatile entities. Further, OTLK &ndash; as one of the speculative stocks under $1 &ndash; takes this unpredictable profile to the extreme. In the trailing one-year period, OTLK suffered a loss of 65%. Since its public market debut in 2016, Outlook lost almost 99%.



Still, there is some limited evidence that the biotech could be de-risked. In particular, analysts on average believe that in 2024, the company could finally print revenue again. The average sales expectation calls for $280,000 while the high-side estimate clocks in at $1.43 million. In 2025, the average forecast rises dramatically to $13.09 million.



On a very positive note, analysts rate shares a <a href="https://www.tipranks.com/stocks/otlk/forecast">consensus strong buy</a> with a $2.22 average price target.



<h2>Affimed (AFMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/penny-stocks-lifting-men-figurines-300x169.jpg" alt="penny stocks"><div>Source: Shutterstock</div></div>Another intriguing but risky biotech enterprise, Affimed (NASDAQ:<a href="https://investorplace.com/stock-quotes/afmd-stock-quote/">AFMD</a>) claims it is devoted to pursuing the untapped potential of the innate immune system. In this way, the protocol gives patients the chance to fight cancer via a more robust approach. Specifically, Affimed seeks to unleash the power of natural killer (NK) cells and other immune cells directly against tumors, facilitating their destruction.



To be fair, the market has a mixed response to AFMD stock. Since the beginning of the year, shares gained more than 6% of equity value. However, in the trailing one-year period, they&rsquo;re down over 26%. However, what&rsquo;s really intriguing is that in the past month, AFMD soared more than 19%. Since November last year, the stock has been charting a series of higher lows.



Financially, analysts only expect 2023 revenue to land at $10.29 million, which would be down 77% from 2022&rsquo;s result. Also, 2024 sales could fade to $6.35 million.



Nevertheless, Wall Street&rsquo;s experts are encouraged at the market potential, pegging shares a buy with a <a href="https://www.tipranks.com/stocks/afmd/forecast">$5 price target</a>. If AFMD stock gets there, we&rsquo;re talking about a return of over 647%.



<h2>Gevo (GEVO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/penny-stocks-finding-magnify-300x169.jpg" alt="A hand holding a magnifying glass over pennies. under-$1 stocks to buy"><div>Source: Shutterstock</div></div>When it comes to the speculative stocks under $1 on this list, Gevo (NASDAQ:<a href="https://investorplace.com/stock-quotes/gevo-stock-quote/">GEVO</a>) could be the riskiest. That&rsquo;s saying something. Since the beginning of the year, GEVO stock dropped over 32% of market value. In the past 52 weeks, shares declined by 57%. We haven&rsquo;t even begun to talk about what the business does and already, some of you may have lost your appetite.



However, this is where circumstances get intriguing for Gevo. <a href="https://www.google.com/finance/quote/GEVO:NASDAQ?hl=en">Per its public profile</a>, the company specializes in renewable chemicals and advanced biofuels. In particular, Gevo is pursuing a business model based on the circular economy; that is, it develops alternatives to petroleum-based products for sustainability purposes.



Analysts are surprisingly optimistic about the company&rsquo;s prospects. For the fiscal year 2023, they anticipate that sales will land at $17.28 million, up substantially from the $1.18 million posted in 2022. Further, at the conclusion of 2024, the top line could hit $19.8 million. If so, that would be a 14.6% increase from 2023&rsquo;s projected revenue.



Finally, the Street&rsquo;s experts rate shares a <a href="https://www.tipranks.com/stocks/gevo/forecast">consensus moderate buy</a> with a $7.50 price target. That comes out to almost 846% upside potential.



On <a href="https://investorplace.com/stock-types/penny-stocks/">Penny Stocks</a> and Low-Volume Stocks:&#8239;With only the rarest exceptions,&nbsp;InvestorPlace&nbsp;does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s&nbsp;writers disclose this fact and warn readers of the risks.



Read More:&#8239;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">Penny Stocks &mdash;&nbsp;How to Profit Without Getting Scammed</a>



On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<div>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/03/7-of-the-best-speculative-stocks-you-can-snag-for-less-than-1/">7 of the Best Speculative Stocks You Can Snag for Less Than $1</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 of the Best Speculative Stocks You Can Snag for Less Than $1

Northern Dynasty Minerals (TSE:NDM) has released an update. Northern Dynasty Minerals Ltd. has initiated two federal court actions challenging the ...

Northern Dynasty Battles EPA Veto and Files Takings Claim

Buy Rating Reaffirmed for Northern Dynasty Minerals Amid Legal Challenges and Local Support

Northern Dynasty Minerals (TSE:NDM) has released an update. Northern Dynasty Minerals Ltd. announced that the State of Alaska has initiated legal a...

Alaska Challenges EPA Veto on Pebble Project

Northern Dynasty Minerals (TSE:NDM) has released an update. Northern Dynasty Minerals Ltd. reports that the US Army Corps of Engineers (USACE) has ...

Northern Dynasty Challenges EPA Veto in Court

AFMD

EMKR

EVTL

GEVO

OTLK

Press Releases

Northern Dynasty Issues Correction

Northern Dynasty: U.S. Army Corps Further Extends the Deadline to Comment on Future Plans

Northern Dynasty Announces US$15 Million Convertible Notes Offering and Up To CAD$3.4 Million Private Placement

Northern Dynasty Closes US$15 Million Convertible Notes Offering and CAD$3.4 Million Private Placement

Northern Dynasty: Pebble Responds to US Supreme Court Decision to Deny Alaska's Petition

Northern Dynasty: Comments on Recent Supreme Court Decision and Anticipated Next Steps

Northern Dynasty Files Two Separate Actions: Seeking to Vacate EPA's Illegal Veto and a Takings Case

Northern Dynasty: State of Alaska Files Action Seeking to Vacate EPA's Unlawful Veto

Northern Dynasty: USACE Updates the Pebble Permitting Process in Light of the EPA Veto

Northern Dynasty Makes Annual Filings

HC Wainwright & Co.